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We present a concept for reducing formation of fibrotic
deposits by inhibiting self-assembly of collagen molecules into
fibrils, a main component of fibrotic lesions. Employing mono-
clonal antibodies that bind to the telopeptide region of a colla-
genmolecule, we found that blocking telopeptide-mediated col-
lagen/collagen interactions reduces the amount of collagen
fibrils accumulated in vitro and in keloid-like organotypic con-
structs. We conclude that inhibiting extracellular steps of the
fibrotic process provides a novel approach to limit fibrosis in a
number of tissues and organs.
Collagen I is themost abundant structural protein of connec-
tive tissues such as skin, bone, and tendon. This protein is first
synthesized as a precursor molecule, procollagen, that is char-
acterized by the presence of a rod-like central triple-helical
domain flanked by short linear telopeptides and globularN-ter-
minal and C-terminal propeptides (1). Single procollagen mol-
ecules are the building blocks for the biologically and mechan-
ically relevant collagen fibrils. Formation of collagen fibrils is
initiated by enzymatic cleavage of the N-terminal and the
C-terminal propeptides. The N-terminal propeptides are
cleaved by a group of enzymes that includes a disintegrin and
metalloprotease with thrombospondin motifs (ADAMTS)-2,
-3, and -14, whereas the C-terminal propeptides are cleaved by
the metalloprotease bone morphogenetic protein 1 (BMP-1)2
and by the other members of a closely related family of mam-
malian tolloid-like metalloproteases (2–4). Such a removal of
procollagen propeptides exposes telopeptides, which by engag-
ing in site-specific intermolecular interactions drive collagen
self-assembly.
In native tissues a precise balance between the processes of
biosynthesis and degradation maintains the physiological
homeostasis of tissue collagens. At the same time, accelerated
biosynthesis is required for proper wound healing, whereas
excessive accumulation of collagen is the hallmark of a number
of localized fibrotic diseases, such as keloids and hypertrophic
scars, and systemic fibrosis, such as systemic scleroderma.
Localized fibrotic reactions are quite common and fre-
quently develop as a consequence of surgical procedures. For
instance, after surgery of the abdomen, the formation of exces-
sive scar tissue around abdominal organs, such as the intestines,
can interfere with the functionality of such organs and may
cause severe pain and even death. Another situation where
excessive scar formation presents amajor complication is in the
eye after glaucoma surgery performed to create a pressure-
maintenance valve. Frequently, however, excessive scar forma-
tion closes this pressure-reducing valve, thereby forcing the
intraocular pressure to rise (5). Moreover, excessive scarring of
the vocal foldsmay severely alter their ability to vibrate, thereby
causing a number of voice disorders (6).
At present, several biological processes critical for develop-
ment of fibrotic lesions are considered potential targets for
inhibitors of fibrosis. These inhibitors aim at (i) reducing
inflammatory processes associated with fibrosis, (ii) inhibiting
biological functions of cytokines and growth factors that pro-
mote fibrosis, (iii) reducing cell proliferation, and (iv) decreas-
ing biosynthesis and processing of procollagens. Because most
of those potential targets are involved not only in pathological
fibrosis but also in a number of physiological processes, their
inhibition is frequently associated with significant adverse
effects (7–11).
Here, we tested a new approach to reduce excessive scarring
by specifically targeting the extracellular process of formation
of collagen fibrils, a main component of fibrotic scars. By
employing custom-designed antibodies that specifically bind to
the C-terminal telopeptide of the 2-chain of collagen I, we
demonstrated that blocking telopeptide-mediated collagen/
collagen interaction limits accumulation of collagen fibrils in
vitro and in organotypic constructs formed by keloid-derived
fibroblasts. Because excessive deposition of collagen fibrils is
characteristic of all fibrotic processes, we predict that the basic
design for the inhibitors of collagen fibril formationwe tested in
a skin-based keloid model will be applicable for reducing a
number of localized and systemic fibrotic changes in other tis-
sues and organs as well.
EXPERIMENTAL PROCEDURES
Purification ofHumanProcollagen I—Procollagen Iwas puri-
fied from cell culture media of normal human dermal fibro-
blasts, as described (12, 13).
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Monoclonal Antibodies—Hybridomas were prepared by a
commercial company (Abgent, Inc. San Diego, CA). Inhibitory
antibodies were raised against a synthetic peptide (GGGYDF-
GYDGDFYRA) whose sequence corresponds to that of the
C-terminal telopeptide of the 2 chain (2Ct). Initial screening
of these antibodies produced by various hybridoma clones was
done with synthetic 2Ct. Finally, the specificity of selected
antibodies to bind a native epitope was tested against intact
human procollagen I and against enzymatically processed pro-
collagen I. In brief, purified procollagen I was processed by
BMP-1 (R&D Systems), lysyl endopeptidase (Lys-C; Roche
Applied Science) or pepsin (Sigma-Aldrich), as described (14,
15). Note that enzymatic cleavage of procollagen I with BMP-1
or Lys-C leaves telopeptide regions intact, whereas digestion of
procollagen with pepsin degrades the telopeptides. At the
same time, digestion with all enzymes employed here pre-
serves the triple-helical region of collagen I. Intact procolla-
gen I and products of its enzymatic cleavage were electro-
phoresed in polyacrylamide gels in denaturing conditions.
Subsequently, protein bands were transferred onto nitrocel-
lulose membranes and detected with primary anti-2Ct
antibody and secondary antibodies conjugated with horse-
radish peroxidase (Sigma-Aldrich). Finally, the protein
bands were visualized by chemiluminescence.
The ability of the anti-2Ct antibody to interact with a
native antigen was also tested by applying unprocessed pro-
collagen I and products of its enzymatic digestion directly
onto nitrocellulose membranes and detecting these proteins
as described above. Moreover, to ensure the lack of any
cross-reactivity of analyzed antibodies with employed
enzymes, BMP-1, Lys-C, and pepsin alone were also loaded
onto nitrocellulose membranes.
Monoclonal antibody, described by Fisher et al. (16) as
LF-41, was raised against a peptide (PLDVGAPDQEFGFDVG-
PVCFL) that corresponds to the C-terminal propeptide of the
pro-1 chain of procollagen I (1Cp). Specificity of the anti-
1Cp antibody to recognize the native epitopes was tested in a
way similar to that described for the anti-2Ct antibody.
Purification of Monoclonal Antibodies—Isotyping of anti-
bodies was performed by Rockland Immunochemicals, Inc.,
Gilbertsville, PA. The anti-2Ct monoclonal antibody (an IgA
isoform with kappa light chains) produced by a selected hybri-
doma clone was purified from cell culture media. In brief, cells
were grown in Dulbecco’s modified Eagle’s medium supple-
mented with 10% fetal bovine serum with reduced IgG content
(Ultra-Low IgG fetal bovine serum, Invitrogen). About 10 liters
of cell culture medium was collected and filtered through glass
fiber filters (Millipore, Inc.) to remove cell debris. Subse-
quently, a protein fraction that included immunoglobulins was
precipitatedwith a 50% saturation of ammoniumsulfate. Apro-
tein pellet was collected by centrifugation and then resus-
pended in a buffer consisting of 0.1 M Tris-HCl, pH 7.8, 120mM
NaCl, and 0.02% NaN3. The anti-2Ct monoclonal antibody
was finally purified by affinity chromatography on a Protein-L
column (Pierce). Column-bound IgA was eluted with 0.1 M gly-
cine, pH 3.0. Collected fractions were immediately neutralized
with a buffer consisting of 1.5MTris-HCl, pH8.0, 120mMNaCl,
and 25 mM EDTA. The purity of the antibody was determined
by electrophoresis in polyacrylamide gels.
The anti-1Cp antibody (an IgG type) was prepared in a sim-
ilar way, but instead of Protein-L, Protein-G was employed for
purification (Pierce). Purified antibodies were dialyzed against
phosphate-buffered saline (PBS) and stored at80 °C.
Cleavage of Procollagen I by BMP-1 in the Presence of Anti-
2Ct Antibody—Because the anti-2Ct antibody was designed
to bind the C-terminal 2 telopeptide, we tested whether its
binding would interfere with the enzymatic activity of BMP-1,
an enzyme that specifically cleaves procollagen I at the C
telopeptide/C propeptide junction (17). Samples containing 50
g/ml procollagen I and 1.2 or 0.2 g/ml purified anti-2Ct
antibody solubilized in a buffer supplemented with 5mMCaCl2
were incubated for 0.5 h at room temperature. Subsequently,
recombinant BMP-1 at a concentration of 25 g/ml was added
to the procollagen I-antibody mixtures, and the samples were
incubated at 37 °C. At defined time points aliquots were with-
drawn and boiledwith a protein-loading buffer. After collecting
all samples, the products of cleavage of procollagen I by BMP-1
were separated in 7.5% polyacrylamide gels. Proteins were visu-
alized by staining with Coomassie Blue (BioSafe Coomassie,
Bio-Rad). Subsequently, employing a computer program, the
pixel intensities of bands corresponding to substrates and prod-
ucts of enzymatic digestion were determined (ImageQuant, GE
Healthcare). Data from three independent measurements were
used to derive rates of cleavage of procollagen I. In addition,
samples that contained the anti-1Cp antibody and those with
no antibodies were prepared and analyzed in a similar way.
To exclude the possibility of the presence of any nonspecific
proteolytic activities derived from enzymes that could co-pu-
rify with procollagen itself or with antibodies, in one set of
experiments we employed EDTA, an inhibitor of BMP-1. In
brief, samples containing procollagen I, BMP-1, and antibodies
were prepared as described above. EDTA was added to these
samples to a final concentration of 10 mM. Subsequently, the
samples were incubated for 4 h at 37 °C and then they were
analyzed by gel electrophoresis as described above.
Fibril Formation Assays in Vitro—De novo collagen fibril for-
mation assays were employed to analyze the inhibitory effect of
the anti-2Ct antibody on collagen fibril formation in vitro, as
described (15, 18–20). In these assays self-assembly of collagen
monomers into fibrils is initiated by enzymatic digestion of pro-
collagen propeptides. In brief, procollagen I at a concentration
230 g/ml was digested with Lys-C (1 g/ml) for 0.5 h at 25 °C,
experimental conditions in which formation of collagen fibrils
does not occur (21). After initial incubation, a possible enzy-
matic digestion of Lys-C-sensitive antibodies was inhibited by
N-p-tosyl-L-lysine chloromethyl ketone (TPCK, Sigma-Al-
drich) added to a final concentration of 1 mM (19, 22). Subse-
quently, the anti-2Ct antibody was added to the Lys-C-pro-
cessed collagen samples at concentrations of 180 or 10g/ml to
achieve collagen/antibody molar ratios of about 1:2 or 10:1,
respectively. Samples were incubated for 0.5 h at room temper-
ature followedby incubation at 37 °C.Todetermine the kinetics
of fibril formation, samples were analyzed at defined time
points, as described (14). In brief, fibril incorporated collagen
was separated from the soluble collagen monomers by centrif-
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ugation. Supernatant was transferred to a fresh tube, and a
fibril-containing pellet was resuspended in 20 l of a buffer
containing 0.1 M Tris-HCl, pH 7.4, 0.4 M NaCl, 25 mM EDTA,
and 0.02% NaN3. After boiling all samples with a protein load-
ing buffer, pellet and supernatant collagen fractions were elec-
trophoresed in 7.5% polyacrylamide gels. Subsequently, protein
bands were visualized by staining with Coomassie Blue, and the
pixel intensities of bands corresponding to the collagen
-chains present in a pellet or in a supernatant fraction were
determined by densitometry. Data from independent studies
were plotted to determine rates of fibril formation, as described
(23). Fibril formation studies in the presence of the anti-1Cp
antibody and those with no antibodies were carried out in a
similar way.
Microscopic Analyses of Morphology of Individual Collagen
Fibrils—For ultrastructural analysis by transmission electron
microscopy, the collagen fibrils were processed as described
(18). In brief, 10-l samples containing fibrils formed for 24 h
were transferred onto 200-mesh Formvar-supported and car-
bon-coated copper grids (Ted Pella, Inc.). Collagen fibrils
deposited on the grids were stained negatively with 1% phos-
photungstate (pH7.0) and visualized by a transmission electron
microscope operating at 75 kV (model H-7000, Hitashi Ltd.,
Japan).
Organotypic Cultures of Keloid-derived Fibroblasts—To test
the ability of the anti-2Ct antibody to limit collagen fibril for-
mation in vivo, we employed a system that utilizes keloid-de-
rived fibroblasts cultured in a three-dimensional environment.
Keloid fibroblasts from patients undergoing elective surgery
were obtained from the Department of Dermatology and Cuta-
neous Biology Research Institute, Yonsei University College of
Medicine, Seoul, South Korea. The cells were maintained in
Dulbecco’s modified Eagle’s medium supplemented with 10%
fetal bovine serum, 2 mM L-glutamine, a mixture of penicillin
and streptomycin, and L-ascorbic acid phosphate magnesium
salt n-hydrate at a concentration of 40 g/ml (WAKO Inc.,
Japan). The organotypic constructs were prepared by employ-
ing three-dimensional sponge-like scaffolds fabricated from
polylactic acid (OPLA, BD Biosciences). Cells were seeded
dynamically into scaffolds by a method adopted fromWang et
al. (24). In brief, the scaffolds were placed into cell culture
chambers of a bioreactor (Sythecon, Inc.) filled with cell sus-
pension containing 2 105 cells/ml, and the cells were allowed
to populate scaffolds for 7 dayswith the culture chambers rotat-
ing at 20 rpm. For fibril formation assay, in vitro individual
scaffolds were transferred into wells of low-cell adhesion cul-
ture plates (Corning, Inc.) and placed into a cell culture incu-
bator onto a platform rotating at 80 rpm. Each day cell culture
media supplemented with the tested antibody at a concentra-
tion of 70 g/ml was exchanged in each well. After 2 weeks of
culture, samples were collected and prepared for analysis.
Inhibition of collagen deposition was also tested in organo-
typic constructs implanted subcutaneously into nude mice
(Nude-Foxn1nu, HARLAN). After 7 days of incubation in cell
culture chambers, four constructs seeded with keloid fibro-
blasts were implanted subcutaneously into an athymic nude
mouse. Subsequently, two of those constructs received a 100-l
dose of an inhibitory antibody present at a concentration of 1.5
mg/ml, injected every 3 days directly into the scaffold and the
surrounding area. Two remaining constructs received injec-
tions of equal amounts of PBS. After 1 month, the mice were
sacrificed, and the scaffolds were prepared for biochemical and
morphological analyses.
In the first set of experiments, in which the organotypic cul-
tures were grown in cell culture conditions, one control group
received the anti-1Cp antibody treatment, and the second one
was treated with PBS only. Because of the limits in supply of the
anti-1Cp antibody in studies with the subcutaneous implants,
the only control group was the one receiving PBS injections.
Analysis of the Total Collagen Content in Keloid-like
Constructs—Scaffolds were rinsed with PBS, cut into two por-
tions, and then lyophilized. Subsequently, the dry mass of
lyophilized samples was measured. Next, one portion of a scaf-
fold was hydrolyzed in 6 N HCl, and the hydroxyproline con-
centration was analyzed to determine collagen content, as
described (25). The remaining portion of a scaffold was utilized
to determine the total protein content.
Microscopic Analyses of Organotypic Keloid-like Constructs—
Keloid-like constructs were harvested and then processed for
histology and electron microscopy analyses. The samples were
stained for collagen deposits with Sirius red. In addition, the
human origin of cells present in the constructs grown subcuta-
neously in mice was confirmed by immunostaining with anti-
human vimentin-specific antibody (Santa Cruz Biotechnology,
Inc.). The stained samples were observed under a microscope
equipped with a digital camera (model Eclipse E600, Nikon,
Japan). For electron microscopy, the samples were fixed in 2%
glutaraldehyde and 1% tannic acid in 0.1 M phosphate buffer
(Electron Microscopy Sciences, Inc.). Subsequently, the sam-
ples were post-fixed in 2% osmium tetraoxide in 0.1 M phos-
phate buffer, rinsed in distilled water, and then stained with 1%
uranyl acetate (Electron Microscopy Sciences). After that, the
samples were embedded in 3% agarose followed by dehydration
in graded concentrations of acetone. Next, the samples were
embedded in Spurr’s resin (Electron Microscopy Sciences).
After polymerization, blocks of samples were sectioned to
70-nm sections with a diamond knife (Diatome, AG, Switzer-
land) mounted on a Leica Ultracut UCT microtome (Leica
Microsystems, Germany). Finally, the sections were post-
stained with 2.5% uranyl acetate in 50% ethanol and sodium
bismuth (Electron Microscopy Sciences) and then observed
with a transmission electron microscope (model H-7000,
Hitashi Ltd., Japan).
Statistics—Collected data were analyzed, and results are pre-
sented as the mean  S.E. for each sample. Comparisons
between control groups andother groupswere performedby an
unpaired, two-tailed t test. In experiments with keloid-like con-
structs grown subcutaneously in mice, a paired t test was
employed. In all tests the  level was set to 0.05. Statistical
analyses were performed with GraphPad Prism Version 5.0
(GraphPad Software Inc.).
RESULTS
Epitope Specificity of Monoclonal Antibodies—Monoclonal
anti-1Cp and anti-2Ct antibodies were purified from cell
culture media of selected hybridomas. The monoclonal anti-
Inhibition of Collagen Fibril Formation
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2Ct antibodies were an IgA type with the kappa light chains,
whereas the anti-1Cp antibody belonged to the IgG class. As
determined by Western blot assays, monoclonal antibodies
produced by selected hybridoma clones specifically recognized
their respective epitopes (Figs. 1 and 2). In particular, the anti-
2Ct antibody-specific signal was apparent only in collagen
variants in which the telopeptides were intact. Specifically, a
group of collagen variants interacting with the anti-2Ct anti-
body included intact procollagen I and procollagen processed
withBMP-1 orwith Lys-C (Fig. 1c).Moreover, we observed that
the 2Ct-specific signal was stronger for a partially processed
pro-2 chain than the signal for the intact pro-2 chain, sug-
gesting more unrestricted access of the tested antibody to the
target telopeptide in the absence of the C-terminal propeptide
(Fig. 1c). There was no apparent signal from the pepsin-di-
gested collagen I in which telopeptides were enzymatically
degraded (Fig. 1c).
Similarly, the anti-1Cp antibody specifically recognized the
C propeptide of the 1 chain of procollagen I. As indicated in
Fig. 1b, the 1 C propeptides present in the intact procollagen
as well as C propeptides cleaved by BMP-1 or Lys-C were rec-
ognized by the anti-1Cp antibody. There was an apparent dif-
ference inmolecularmasses of products generated by digestion
of the C propeptides with Lys-C and BMP-1, most likely due to
the differences in location of the specific cleavage sites recog-
nized by these enzymes (Fig. 1b). The lack of binding of the
anti-1Cp antibody to the pepsin-treated procollagen in which
the C propeptides were degraded provides even more evidence
for its epitope-specific binding (Fig. 1b).
As determined by slot-blot assays, both the anti-1Cp and
anti-2Ct antibodies were able to interact with native epitopes
(Fig. 2). Specifically, the antibodies interacted with the intact
procollagen I and with products generated by cleavage of pro-
collagen I with BMP-1 or Lys-C. In contrast, the product gen-
erated by digestion with pepsin was not recognized by analyzed
FIGURE 1.Analysis of specificity of epitope recognition by the anti-1Cp
and anti-2Ct antibodies. Panel a depicts intact procollagen I and products
of its digestion by BMP-1, Lys-C, or pepsin separated in polyacrylamide gels
and stained with Coomassie Blue. Specific epitopes present in proteins rep-
resented in panel a were analyzed by Western blot with the anti-1Cp anti-
body (panel b) or with the anti-2Ct antibody (panel c). In panel d schematics
of domains in intact procollagen I or in products of its digestion by BMP-1,
Lys-C, or pepsin are presented. In addition, molecular mass markers are pre-
sented. Pro, intact procollagen I; pN, procollagen variant in which the C-ter-
minal propeptide have been cleaved by BMP-1; Col-Lys-C, collagen I variant,
includes telopeptides, generated by enzymatic cleavage of procollagen with
Lys-C; Col-Peps, collagen I variant, with telopeptides absent, generated by
enzymatic cleavage of procollagen I with pepsin; Pro-1, pro-1 chain of pro-
collagen I; Pro-2, pro-2 chain of procollagen I; dPro-1 and dPro-2, par-
tially processed pro- chains of procollagen I; pN-1 and pN-2, procollagen
 chains in which the C-terminal propeptides were cleaved by BMP-1;1 and
2, collagen I  chains; a-1Cp and a-2Ct, antibodies against the C-terminal
propeptide of the 1 chain and the C-terminal telopeptide of the 2 chain of
procollagen I, respectively; 1Cp and d1Cp, C propeptide derived by cleav-
age of the procollagen 1 chain with BMP-1 or Lys-C, respectively; Np, Nt, Ct,
and Cp, N-terminal propeptides, N-terminal telopeptides, C-terminal
telopeptides, and C-terminal propeptides of procollagen I, respectively.
FIGURE 2. Slot blot analysis of the specificity of recognition of native
epitopesby theanti-1Cpandanti-2Ctantibodies.Panel a shows results
of assays of binding of the anti-1Cp antibody to native procollagen I and to
the products of its cleavage with BMP-1, Lys-C, or pepsin. Panel b depicts
results of analyses of binding of the anti-2Ct antibody to the same proteins.
In addition, both panels show the lack of binding of analyzed antibodies to
BMP-1, Lys-C, and pepsin. Pro, procollagen I;  indicates samples digested
with BMP-1, Lys-C, or pepsin; asterisks indicate positions of proteins present
on nitrocellulose membranes but not detected by analyzed antibodies.
Inhibition of Collagen Fibril Formation
25882 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 283•NUMBER 38•SEPTEMBER 19, 2008
 at Y
O
N
SEI U
N
IV
ERSITY
 on O
ctober 29, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
antibodies. As demonstrated in Fig. 2, the enzymes themselves
did not react with tested antibodies.
Processing of the C Propeptide by BMP-1 in Vitro in the Pres-
ence of the Anti-2Ct Antibody—Because the anti-2Ct anti-
body binds to the C-terminal telopeptide, we tested whether its
binding could hinder BMP-1 cleavage of the Ala-Asp bond
present at the C telopeptide/C propeptide junction (Fig. 3). As
demonstrated in Table 1, the presence of the anti-2Ct anti-
body decreased the rate of cleavage of procollagen chains in a
concentration-dependent fashion (Fig. 3 and Table 1). Under
the same conditions, therewas no statistically significant differ-
ence between the rates of cleavage of procollagen  chains by
BMP-1 in control samples containing the anti-1Cp antibody
and those to which no antibody was added (Fig. 3 and Table 1).
Employing EDTA, we determined that there was no proteo-
lytic activity other than that derived from BMP-1. In particular,
in the presence of EDTA there was not any detectable cleavage
of procollagen I (Fig. 3d).
Kinetics of Self-assembly of Collagen and Morphology of
Fibrils Formed in Vitro in the Presence of the Anti-2Ct
Antibody—In a number of in vitro assays it has been estab-
lished that de novo fibril formation, i.e. where individual col-
lagen molecules derived from enzyme-processed procolla-
gen self-assemble into fibrils, is characterized by distinct
phases of nucleation, propagation, and equilibrium (21).
Here, in vitro fibril formation assays demonstrated that
binding of the anti-2Ct antibody to the C-terminal 2
telopeptide decreased both the rate of fibril formation and
the amount of accumulated collagen fibrils (Fig. 4a, Table 1).
By employing various concentrations of inhibitory antibod-
ies, we demonstrated that the decrease in the rates of fibril
formation and in the amounts of accumulated fibrils at equi-
librium was concentration-dependent (Table 1). In contrast,
the presence of the anti-1Cp antibody did not have any
significant effects on the kinetics of fibril assembly or on the
total amount of accumulated fibrils (Fig. 4a, Table 1).
In addition to electrophoretic assays of the kinetics of forma-
tion of fibrils and densitometric quantitation of their amounts,
electron microscopy was employed to observe the morphology
of individual collagen fibrils. These assays demonstrated that
regardless of quantitative differences in the amounts of accu-
mulated fibrils, the morphology of individual fibrils formed in
the presence of tested antibodies was similar to that of a non-
treated control. On average, fibrils formed in the control group
and those assembled in the presence of antibodies were 100 nm
in diameter. In addition, as evident by the uniform banding
pattern, all analyzed fibrils were characterized by correct pack-
ing of collagen molecules (Fig. 4b).
Collagen Content and Morphology of Collagenous Matrices
Formed in Organotypic Cultures in the Presence of the Anti-
2Ct Antibody—Keloid-derived fibroblasts were cultured in
the presence of the anti-2Ct or the anti-1Cp antibodies in
scaffolds in cell culture conditions and under the skin of nude
mice. Subsequently, the total collagen content and the mor-
phology of those organotypic constructs were analyzed. As
indicated in Table 1, there was a statistically significant reduc-
tion of accumulated collagen in keloid constructs grown under
cell culture conditions in the presence of the anti-2Ct anti-
body. In contrast, the collagen content in constructs grown in
the presence of the anti-1Cp antibody was similar to that of
the control group (Table 1). Similarly, in keloid-like constructs
grown subcutaneously in mice, the total amount of collagen
decreased in samples treated with the anti-2Ct antibody in
comparison to nontreated controls (Table 1).
General morphological analysis of keloid-like constructs
formed subcutaneously in mice showed that they were well
FIGURE 3. Kinetics of cleavage of procollagen I by BMP-1 in the presence
of the anti-1Cp or the anti-2Ct antibody. Panel a illustrates kinetics of
cleavage of procollagen I by BMP-1 in the absence of antibodies, whereas
panels b and c showkinetics of cleavageof procollagen I in thepresenceof 1.2
g/ml anti-1Cp or the anti-2Ct antibody, respectively. Time points at
which samples were analyzed are indicated. In panels b and c, protein bands
corresponding to BMP-1 and to antibodies employed in this study are also
indicated. In addition, molecular mass markers are presented in the left lanes
of all panels. Panel d presents analysis of the specificity of cleavage of procol-
lagen I with BMP-1. Note that in the presence of EDTA there was no cleavage
of a procollagen substrate by BMP-1, thereby indicating the absence of other
active enzymes. Pro-1, pro-1 chain of procollagen I; Pro-2, pro-2 chain of
procollagen I; pN-1 and pN-2, procollagen chains inwhich theC-terminal
propeptides were cleaved by BMP-1; C1 and C2, C propeptides cleaved off
respective procollagen chains by BMP-1; a-1Cp and a-2Ct, antibodies
against the C-terminal propeptide of the 1 chain and the C-terminal
telopeptide of the 2 chain of procollagen I, respectively; H-a-1Cp and L-a-
1Cp, heavy and light chains of an anti-1Cp immunoglobulin, respectively;
H-a-2Ct and L-a-2Ct, heavy and light chains of an anti-2Ct immunoglob-
ulin, respectively; and indicate the presence or the absence of selected
compounds.
Inhibition of Collagen Fibril Formation
SEPTEMBER 19, 2008•VOLUME 283•NUMBER 38 JOURNAL OF BIOLOGICAL CHEMISTRY 25883
 at Y
O
N
SEI U
N
IV
ERSITY
 on O
ctober 29, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
organized into tissue-like structures (Fig. 5). As evident by the
positive staining with antibody, which detects human vimentin
and does not cross-react withmouse vimentin, the cells present
in the subcutaneous constructs were fibroblasts derived from
human keloid (Fig. 5d). Collagen-specific staining of samples
demonstrated the presence of collagenous matrices deposited
in the scaffold (Fig. 5, e and f). In samples treated with the
anti-2Ct antibody, however, the apparent density of collage-
nous deposits was relatively lower than that seen in control (Fig.
5, e and f). Similarly, in the presence of the anti-2Ct antibody,
the apparent density of collagen fibrils in the keloid-like con-
structs as seen under an electron microscope was relatively
lower than in control samples (Fig. 5, g and h).
DISCUSSION
Fibrotic scarring is a reactive process that ismodulated by the
local proliferation of cells responsible for fibrosis and by altered
regulation of various metabolic reactions governing biosynthe-
sis and degradation of the connective tissue components. In
addition, fibrotic processes are influenced by cytokines and
growth factors, a groupof diversemolecules derived fromblood
cells, such as platelets, or elaborated locally by mesenchymal
and epithelial cells (26).
A number of processes and factors critical for the progres-
sion of fibrosis have been identified as targets to limit fibrotic
scarring. Because most of these potential targets have broad
biological functions, many of which are not related to fibrosis,
their inhibition frequently leads to significant adverse effects.
Unlike prior approaches, which have attempted to limit
excessive scarring by targeting upstream intracellular events,
our strategy focuses on downstream extracellular events of col-
lagen fibril formation, a process that directly contributes to for-
mation of fibrotic deposits. The rationale for such an approach
is that collagen fibril formation depends on site-specific inter-
actions between telopeptides of one collagen molecule and a
specific region located within a triple-helix of an interacting
partner molecule (27). Free collagen molecules that do not
incorporate into fibrils are then readily accessible for degrada-
tion by a number of enzymes present in the extracellular space
(28, 29). The telopeptide/triple-helix interaction is particularly
critical at the initial stages of fibril assembly, and our earlier
studies demonstrated that in vitro fibril formation is completely
blocked by peptides that compete for the telopeptide binding
sites (28).
Although our method of blocking the collagen/collagen
interaction represents a novel approach to limit fibrotic scar
formation, conceptually similar approaches were tested in
other pathologies. For instance, inhibition of protein aggrega-
tion has been tested as a method to prevent formation of insol-
uble amyloid plaques, a main feature of Alzheimer disease, that
are formed in a process of fibrillation from an amyloid precur-
sor protein (30). Moreover, inhibitors of fibrillation of sickle-
cell hemoglobin have been tested in clinical trials, and inhibi-
tors of systemic amyloidosis have been shown to be effective in
animal models (31, 32).
Collagen fibril formation is not the only process that depends
on telopeptide/triple-helix interaction. Site-specific binding of
TABLE 1
Summary of results on inhibitory effects of the anti-2Ct antibody on BMP-1 cleavage, kinetics of fibril formation, and accumulation of
collagen in keloid-like constructs
NA, not applicable.
Control () Anti-2Ct () Anti-1Cp
Mean S.E. (% of control) Mean S.E. (% of control) Mean S.E. (% of control)
Rate of cleavage of procollagen I with
BMP-1 in vitro (g/min/ml)
0.22 0.01; n 3 (100%) a0.04 0.02; n 3; p 0.001 (18%) b0.18 0.009; n 3; p 0.07 (82%)
b0.03 0.003; n 3; p 0.0001 (14%)
Rate of fibril formation in vitro (g/min/ml) 0.27 0.046; n 4 (100%) c0.053 0.02; n 4; p 0.005 (20%) d0.25 0.054; n 4; p 0.8 (93%)
d0.132 0.003; n 4; p 0.02 (49%)
Total accumulated fibrils in vitro (g/ml) 72.08 8.3; n 4 (100%) c21.87 7.04; n 3; p 0.007 (30%) d73.38 10.01; n 4; p 0.9 (100%)
d40.77 6.11; n 4; p 0.02 (57%)
Accumulation of collagen in keloid-like
constructs grown in cell culture conditions
(collagen (mg)/total protein (mg))
0.104 0.016; n 3 (100%) 0.026 0.004; n 5; p 0.0008 (25%) 0.117 0.01; n 2; p 0.6 (113%)
Accumulation of collagen in keloid-like
constructs grown subcutaneously in nude
mice (collagen (mg)/total protein (mg))
0.495 0.07; n 7 (100%) 0.209 0.03; n 8; p 0.001 (42%) NA
a0.2 g/ml anti-2Ct was used.
b1.2 g/ml anti-2Ct or the anti-1Cp was used.
c The collagen/antibody molar ratio was 1:2.
d The collagen/antibody molar ratio was 10:1; NA, not assayed.
FIGURE 4. Kinetics of de novo formation of collagen fibrils. Panel a repre-
sents analysis of collagenpresent in fibril andmonomer fractions at indicated
time points. The upper row depicts control samples, whereas themiddle and
lower rows show kinetics of fibril formation in the presence of 180 g/ml
anti-1Cp and anti-2Ct antibodies, respectively. In the left lane molecular
mass markers are indicated. Panel b demonstrates morphology of individual
fibrils formed in the presence or absence of tested antibodies. P, pellet frac-
tions that represents collagen fibrils; S, supernatant fractions that represents
collagenmonomers;1 and2, collagen I chains;Ctrl, fibril formation in the
absence of antibodies; a-1Cp and a-2Ct, fibril formation in the presence of
antibodies against the C-terminal propeptide of the 1 chain or the C-termi-
nal telopeptide of the 2 chain of procollagen I, respectively.
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telopeptides positions them in a way that enables formation of
intermolecular cross-links, critical for stabilization of collagen
fibrils, between specific hydroxylysine residues (33). Thus, by
blocking telopeptide/triple-helix binding, our approach not
only prevents formation of new fibrils, but it may also prevent
formation of cross-links in existing fibrils. Because poorly
cross-linked collagen molecules are not fully functional and
they are readily degraded by proteolytic enzymes, blocking
telopeptide-mediated interactions may further reduce forma-
tion of excessive collagenous deposits in fibrotic scars.
Although collagen fibrils in fibrotic scars are heterotypic and
consist mainly of collagen I, collagen III, and collagen V, we
postulate that specific blocking collagen I/collagen I interaction
will most likely prevent not only formation of homotypic colla-
gen I fibrils but also formation of their heterotypic assemblies.
This notion is based on the observation that incorporation of
collagen III and collagen V into fibrils requires the presence of
preassembled collagen I and that these proteins alone do not
form stable fibrils (13, 34, 35).
Because the steric hindrance imposed by the presence of a
bulky C propeptide prevents tight packing of collagen mole-
cules required for the correct structure of a fibril, processing of
this propeptide by BMP-1 is critical for fibril formation (21).
Here, we demonstrated that a telopeptide binding antibody
reduces the rate of cleavage of the C-terminal propeptides by
BMP-1. Based on this observation, we postulate that such a
reduction could offer an additional
mechanism for reducing formation
of fibrillar deposits. The idea of
blocking BMP-1 to limit fibrosis was
suggested by others, and a number
of inhibitors of BMP-1 have been
developed and tested as potential
inhibitors of fibrosis (36). At the
same time, however, it has been
demonstrated that, in addition to
procollagen I, BMP-1 cleaves other
substrates and that its activity is
critical for a number of processes
not related to fibrosis (37–39).
Moreover, it has been shown that in
mice with targeted ablation of the
gene for BMP-1, procollagen is still
processed, thereby indicating an
involvement of other members of
the family of tolloid-related metal-
loproteases (40, 41). These observa-
tions significantly reduce the useful-
ness of BMP-1 to serve as a target to
limit fibrosis. In contrast, our
approach, in which a substrate
rather than an enzyme is a target for
inhibition, makes altering cleavage
of the C-propeptide of procollagen I
both specific and feasible.
We demonstrated that blocking
2-Ct telopeptides limits fibril for-
mation both in vitro and in organo-
typic keloid-like constructs. As an in vitro system provides a
more controllable experimental environment suitable for
measuring rates of enzymatic processing of procollagen by
BMP-1 and rates of fibril formation, the keloid-like system we
employed provides amore biologically relevantmodel in which
active anabolic and catabolic processes resemble, to a certain
extent, those occurring in native tissues. With this model we
demonstrated that anti-2Ct antibody significantly reduced
the total amount of deposited collagen but at the same time did
not alter overall morphology of individual fibrils formed in its
presence (Fig. 4b). As indicated in Table 1, the extent of inhibi-
tion of collagen accumulation was greater in keloid-like con-
structs cultured in cell culture conditions than in those grown
subcutaneously in mice. We postulate that this difference was
mainly due to more efficient diffusion of antibodies to specific
epitopes and perhaps slower rates of their degradation in cell
culture conditions.
Overall, our research presents experimental support for a
new concept that excessive deposition of fibrotic tissue can be
limited by inhibition of formation of collagen fibrils. In the
future, humanized antibodies or small compoundswith specific
and high affinities for binding collagen telopeptides may
advance the effectiveness of the presented approach to inhibit
formation of localized fibrotic changes and also make it appli-
cable for limiting systemic fibrotic diseases.
FIGURE 5.Analysis ofmorphologyof keloid-like constructs formed subcutaneously innudemice. Panel a
shows keloid-like constructs (arrow) implanted under skin of a mouse. Panel b presents a sponge-like scaffold
that was employed to host human keloid-derived fibroblasts. Panel c represents overall morphology of a
keloid-like construct harvested after 1 month of culture under skin of a nude mouse. Panel d demonstrates
immunostaining for human-specific vimentin to confirm human origin of cells cultured in subcutaneous scaf-
folds, whereas panels e and f present Sirius red staining of collagen deposits. Panels g and h show electron
microscopy images of collagen fibrils present in sections of keloid-like constructs. Individual panels show
morphology of collagenous matrices formed in the absence (e and g) or presence (f and h) of inhibitory
antibodies. Ctrl, keloid-like constructs cultured in the absence of antibodies; a-2Ct, keloid-like constructs
cultured in the presence of inhibitory antibodies against the C-terminal telopeptide of the 2 chain of procol-
lagen I. Scale bars are included for specific sets of panels.
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